JP2005532051A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005532051A5 JP2005532051A5 JP2004518186A JP2004518186A JP2005532051A5 JP 2005532051 A5 JP2005532051 A5 JP 2005532051A5 JP 2004518186 A JP2004518186 A JP 2004518186A JP 2004518186 A JP2004518186 A JP 2004518186A JP 2005532051 A5 JP2005532051 A5 JP 2005532051A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- amino acid
- light chain
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000539 amino acid group Chemical group 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 13
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 12
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 7
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 108091026890 Coding region Proteins 0.000 claims 4
- 102000005962 receptors Human genes 0.000 claims 4
- 108020003175 receptors Proteins 0.000 claims 4
- 239000013604 expression vector Substances 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 2
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 2
- 239000012636 effector Substances 0.000 claims 2
- 206010017758 gastric cancer Diseases 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 claims 1
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 claims 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 1
- 239000002202 Polyethylene glycol Substances 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 229940044683 chemotherapy drug Drugs 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 201000004101 esophageal cancer Diseases 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 230000009826 neoplastic cell growth Effects 0.000 claims 1
- 229920001223 polyethylene glycol Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39299302P | 2002-07-01 | 2002-07-01 | |
| US41737202P | 2002-10-09 | 2002-10-09 | |
| PCT/US2003/020762 WO2004002431A2 (en) | 2002-07-01 | 2003-07-01 | Humanized anti-lymphotoyin beta receptor antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005532051A JP2005532051A (ja) | 2005-10-27 |
| JP2005532051A5 true JP2005532051A5 (enExample) | 2006-08-17 |
Family
ID=30003289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004518186A Pending JP2005532051A (ja) | 2002-07-01 | 2003-07-01 | ヒト化抗リンホトキシンβレセプター抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7429645B2 (enExample) |
| EP (1) | EP1539793A4 (enExample) |
| JP (1) | JP2005532051A (enExample) |
| CN (1) | CN1678625A (enExample) |
| AR (1) | AR040367A1 (enExample) |
| AU (1) | AU2003248782A1 (enExample) |
| CA (1) | CA2491480A1 (enExample) |
| NZ (1) | NZ537965A (enExample) |
| TW (1) | TW200416044A (enExample) |
| WO (1) | WO2004002431A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| PL195264B1 (pl) * | 1998-10-09 | 2007-08-31 | Biogen Idec Inc | Zastosowania limfotoksyny-beta lub czynnika blokującego receptor limfotoksyny-beta, zastosowanie polipeptydu z domeną wiążacą ligand ludzkiego LT-beta-R oraz zastosowania czynnika blokującego receptor limfotoksyny-beta i/lub szlak sygnalizacji HVEM |
| EP1326897A2 (en) * | 2000-10-13 | 2003-07-16 | Biogen, Inc. | Humanized anti-lt-beta-r antibodies |
| EP1583503A4 (en) * | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF |
| CN1753692A (zh) * | 2002-12-20 | 2006-03-29 | 比奥根艾迪克Ma公司 | 淋巴毒素β受体药剂与化疗剂的联合用药 |
| AU2004252171B2 (en) * | 2003-06-27 | 2011-04-21 | Biogen Ma Inc. | Modified binding molecules comprising connecting peptides |
| JP2005241389A (ja) * | 2004-02-25 | 2005-09-08 | Ochiyanomizu Jiyoshi Univ | 蛍光標識糖鎖の特異的固定化試薬および固定化方法 |
| KR20060132006A (ko) | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| WO2008042436A2 (en) | 2006-10-03 | 2008-04-10 | Biogen Idec Ma Inc. | Biomarkers and assays for the treatment of cancer |
| UA94484C2 (uk) | 2006-10-12 | 2011-05-10 | Дженентек, Інк. | Антитіла до лімфотоксину-альфа |
| AU2007311052B2 (en) * | 2006-10-20 | 2014-01-16 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
| WO2009000099A2 (en) | 2007-06-25 | 2008-12-31 | Esbatech Ag | Methods of modifying antibodies, and modified antibodies with improved functional properties |
| CN102341411A (zh) * | 2008-12-31 | 2012-02-01 | 比奥根艾迪克Ma公司 | 抗-淋巴细胞毒素抗体 |
| EP2569012A4 (en) | 2010-05-11 | 2013-10-30 | Aveo Pharmaceuticals Inc | ANTI-FGFR2 ANTIBODY |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| KR20220130687A (ko) * | 2019-12-11 | 2022-09-27 | 시락 게엠베하 인터내셔날 | Ltbr 및 edb 결합 도메인을 포함하는 다중특이성 결합 분자 및 이의 용도 |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CR20240246A (es) * | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| WO2023218320A1 (en) * | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
| WO2025012620A1 (en) | 2023-07-07 | 2025-01-16 | Mestag Therapeutics Ltd | Binding constructs |
| EP4527851A1 (en) | 2023-09-22 | 2025-03-26 | Bayer Aktiengesellschaft | Bispecific antibodies binding ltbr and lrrc15 |
| WO2025172587A1 (en) | 2024-02-16 | 2025-08-21 | Mestag Therapeutics Ltd | Binding constructs |
| WO2025172588A1 (en) | 2024-02-16 | 2025-08-21 | Mestag Therapeutics Ltd | Bispecific constructs directed against fap and ltbr |
| WO2025221736A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| JPH06501456A (ja) | 1990-06-27 | 1994-02-17 | バイオジェン，インコーポレイテッド | 表面複合リンホトキシン |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| EP0672143B1 (en) | 1992-12-04 | 2008-06-04 | Biogen Idec MA Inc. | Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof |
| PT809510E (pt) * | 1995-01-26 | 2004-09-30 | Biogen Inc | Complexos de linfotoxina-alfa/beta e anticorpos receptores de anti-linfotoxina-beta como agentes anti-tumor |
| US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| IL137489A0 (en) | 1998-01-30 | 2001-07-24 | Univ New York | Pharmaceutical compositions containing inhibitors of the lymphotoxin pathway |
| US7060667B1 (en) * | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
| GB9809839D0 (en) * | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| EP1326897A2 (en) * | 2000-10-13 | 2003-07-16 | Biogen, Inc. | Humanized anti-lt-beta-r antibodies |
| CN1753692A (zh) * | 2002-12-20 | 2006-03-29 | 比奥根艾迪克Ma公司 | 淋巴毒素β受体药剂与化疗剂的联合用药 |
| EP1583503A4 (en) * | 2002-12-20 | 2006-08-09 | Biogen Idec Inc | POLYVALENT LYMPHOTOXIN BETA RECEPTOR AGONISTS AND THERAPEUTIC USE THEREOF |
| KR20060132006A (ko) * | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
-
2003
- 2003-07-01 CA CA002491480A patent/CA2491480A1/en not_active Abandoned
- 2003-07-01 NZ NZ537965A patent/NZ537965A/en unknown
- 2003-07-01 AR ARP030102391A patent/AR040367A1/es unknown
- 2003-07-01 WO PCT/US2003/020762 patent/WO2004002431A2/en not_active Ceased
- 2003-07-01 TW TW092117964A patent/TW200416044A/zh unknown
- 2003-07-01 CN CNA038207214A patent/CN1678625A/zh active Pending
- 2003-07-01 EP EP03762296A patent/EP1539793A4/en not_active Withdrawn
- 2003-07-01 AU AU2003248782A patent/AU2003248782A1/en not_active Abandoned
- 2003-07-01 JP JP2004518186A patent/JP2005532051A/ja active Pending
-
2004
- 2004-12-23 US US11/021,819 patent/US7429645B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005532051A5 (enExample) | ||
| CN110799539B (zh) | 抗4-1bb抗体及其制备和使用方法 | |
| AU2003230183B2 (en) | Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency | |
| JP2020520370A5 (enExample) | ||
| CN103030695B (zh) | 抗c‑Met人源化抗体及含其的预防或治疗癌症用的药物组合物 | |
| JP2013502913A5 (enExample) | ||
| JP2020501531A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| CN111944050A (zh) | 一种抗b7-h3抗体及其应用 | |
| JP2010513303A5 (enExample) | ||
| CN107735093A (zh) | Cd123抗体和其结合物 | |
| AU2017226510A1 (en) | PDL-1 antibody, pharmaceutical composition thereof, and uses thereof | |
| JP2019205480A5 (enExample) | ||
| WO2023036137A1 (en) | Process for preparing highly homogenous antibody-drug conjugates for engineered antibodies | |
| JP2013534515A5 (ja) | 受容体型チロシンキナーゼｃ−Ｍｅｔに対する抗体 | |
| JP2020515577A5 (enExample) | ||
| US20220185907A1 (en) | Anti-cd19/anti-cd38 common light chain bispecific antibodies | |
| WO2021173844A1 (en) | C19 c38 bispecific antibodies | |
| US20250034273A1 (en) | Composition of multispecific antibodies targeting cadherin-17-expressing tumors and method of making and using thereof | |
| AU2018285523A1 (en) | Antibody drug conjugates that bind LGR5 | |
| CN105828841A (zh) | 抗-efna4抗体-药物缀合物 | |
| CN112805297A (zh) | 抗人类pd-l1抗体及其用途 | |
| US20240309116A1 (en) | Antibodies against ror1 and uses thereof | |
| JPWO2020218951A5 (enExample) | ||
| JPWO2021190622A5 (enExample) |